Pemphigus Disease and Area Index: Unmet Needs in the Real-World Management of Pemphigus

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share this content! On (X network) By

Pemphigus Disease and Area Index: Unmet Needs in the Real-World Management of Pemphigus Publisher Pubmed

Mahmoudi H¹ ; Toosi R¹ ; Salehifarid A¹ ; Daneshpazhooh M¹

Show Affiliations

1. Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Oral Diseases Published:2023

Abstract

Over the past few decades, a number of scoring instruments have been developed to assess the severity and activity of autoimmune bullous diseases (AIBDs) (Daneshpazhooh et al., 2019; Nili et al., 2020; Nili et al., 2021; Nili et al., 2022). The Pemphigus Disease Area Index (PDAI), developed by the International Pemphigus Definitions Group, is an easy-to-use, quick, and reliable method for determining pemphigus severity. As a reliable and effective tool in clinical trials, PDAI may also have some limitations and might require some revisions to be used on a daily basis. Here, we propose some recommendations to improve the use of PDAI in the clinical setting. © 2023 Wiley Periodicals LLC.

Related Docs

View other Related Docs

1. Factors Associated With the Healing Time of Pemphigus Vulgaris Oral Lesions: A Prospective Study, Oral Diseases (2023)

2. Current Status and Prospects for the Diagnosis of Pemphigus Vulgaris, Expert Review of Clinical Immunology (2021)

3. Rituximab in Practice: Clinical Evaluation of Patients With Pemphigus After Rituximab Administration, Dermatologic Therapy (2021)

4. Comparison of Topical Nanocolloidal Silver Formulation Use With Eosin 2% Solution in Management of Hard-To-Heal Ulcers in Patients With Pemphigus Vulgaris, Journal of Wound Care (2020)

5. Iranian Guideline for Rituximab Therapy in Pemphigus Patients, Dermatologic Therapy (2019)

6. Applicability of Glucocorticoid Toxicity Index in Pemphigus: Comparison Between Two Groups of Rituximab-Treated and Rituximab-Naive Patients, Dermatologic Therapy (2022)

7. Adverse Outcome and Severity of Covid-19 in Patients With Autoimmune Bullous Diseases: A Historical Cohort Study, Dermatologic Therapy (2022)

8. Covid-19: The Experience From Iran, Clinics in Dermatology (2021)

Experts (# of related papers)

View all Related Experts

Maryam Daneshpajooh (30)

Hamid Reza Mahmoodi (26)

Other Related Docs

9. Pregnancy Outcomes in Women With Pemphigus Exposed to Rituximab Before or During Pregnancy, International Journal of Women's Dermatology (2022)

10. Intralesional Injection of Biosimilar Rituximab in Recalcitrant Mucocutaneous Lesions of Patients With Pemphigus Vulgaris: A Pilot Study, Dermatologic Therapy (2020)

11. Are Sites of Primary Lesions in Pemphigus Vulgaris More Prone to Relapse?, Oral Diseases (2024)

12. Rituximab in Childhood and Juvenile Autoimmune Bullous Diseases As First-Line and Second-Line Treatment: A Case Series of 13 Patients, Journal of Dermatological Treatment (2020)

13. Rituximab Monotherapy in Mild Pemphigus, Journal of Dermatological Treatment (2022)

14. Efficacy and Safety of Biosimilar Rituximab in Patients With Pemphigus Vulgaris: A Prospective Observational Study, Journal of Dermatological Treatment (2021)

15. Estimated Cut-Off Values for Pemphigus Severity Classification According to Pemphigus Disease Area Index (Pdai), Autoimmune Bullous Skin Disorder Intensity Score (Absis), and Anti-Desmoglein 1 Autoantibodies, BMC Dermatology (2020)

16. Burden of Pemphigus Vulgaris With a Particular Focus on Women: A Review, International Journal of Women's Dermatology (2022)

17. Pemphigus Scalp Lesions: Is Trichoscopy Helpful in Clinical Diagnosis?, International Journal of Dermatology (2021)

18. Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab, International Journal of Women's Dermatology (2019)

19. What Is Novel in the Clinical Management of Pemphigus Vulgaris?, Expert Review of Clinical Pharmacology (2024)

20. Odss Vs. Absis and Pdai Oral Parts in Pemphigus Vulgaris: Inter-Rater Reliability and Testing Times, Oral Diseases (2023)

21. Anagen Hair Loss, Anti-Desmoglein 1, and Pemphigus Disease Area Index: A Signifi Cant Relationship?; [Anagener Haarverlust, Anti-Desmoglein 1 Und Pemphigus Disease Area Index: Ein Signifi Kanter Zusammenhang?], JDDG - Journal of the German Society of Dermatology (2017)

22. Prevalence of Fungal Infections in Pemphigus Patients: A Systematic Review and Meta-Analysis, Mycoses (2024)

23. Desquamative Gingivitis in a Pemphigus Vulgaris Patient Resistant to Rituximab, Dermatologic Therapy (2020)

24. Investigating Expression Pattern of Eight Immune-Related Genes in Pemphigus Patients Compared With the Healthy Controls and After Rituximab Therapy: Potential Roles of Ctla4 and Fcgr3a Genes Expression in Outcomes of Rituximab Therapy, Dermatologic Therapy (2020)

25. Pustular Eruption After Biosimilar Rituximab Infusion: Report of Acute Generalized Exanthematous Pustulosis in Two Patients With Pemphigus, International Journal of Dermatology (2022)

26. A Systematic Review on Efficacy, Safety, and Treatment-Durability of Low-Dose Rituximab for the Treatment of Pemphigus: Special Focus on Covid-19 Pandemic Concerns, Immunopharmacology and Immunotoxicology (2021)

27. Drug-Induced Pemphigus: A Systematic Review of 170 Patients, International Immunopharmacology (2021)

28. Paradoxical Reaction to Rituximab in Patients With Pemphigus: A Report of 10 Cases, Immunopharmacology and Immunotoxicology (2020)

29. Elevated Serum Level of B-Cell Activating Factor (Baff) After Rituximab Therapy in Pemphigus Vulgaris Patients Suggests a Possible Therapeutic Efficacy of B-Cell Depletion Therapies Combined With Anti-Baff Agents, International Journal of Dermatology (2023)

30. Comparing Early and Late Treatments With Rituximab in Pemphigus Vulgaris: Which One Is Better?, Archives of Dermatological Research (2019)

31. Pemphigus Patients With Initial Negative Levels of Anti-Desmoglein: A Subtype With Different Profile?, Dermatologic Therapy (2022)

Style	Citing Format
MLA	Mahmoudi H, et al.. "Pemphigus Disease and Area Index: Unmet Needs in the Real-World Management of Pemphigus." Oral Diseases, vol. , no. , 2023, pp. -.
APA	Mahmoudi H, Toosi R, Salehifarid A, Daneshpazhooh M (2023). Pemphigus Disease and Area Index: Unmet Needs in the Real-World Management of Pemphigus. Oral Diseases, (), -.
Chicago	Mahmoudi H, Toosi R, Salehifarid A, Daneshpazhooh M. "Pemphigus Disease and Area Index: Unmet Needs in the Real-World Management of Pemphigus." Oral Diseases , no. (2023): -.
Harvard	Mahmoudi H et al. (2023) 'Pemphigus Disease and Area Index: Unmet Needs in the Real-World Management of Pemphigus', Oral Diseases, (), pp. -.
Vancouver	Mahmoudi H, Toosi R, Salehifarid A, Daneshpazhooh M. Pemphigus Disease and Area Index: Unmet Needs in the Real-World Management of Pemphigus. Oral Diseases. 2023;():-.
BibTex	@article{ author = {Mahmoudi H and Toosi R and Salehifarid A and Daneshpazhooh M}, title = {Pemphigus Disease and Area Index: Unmet Needs in the Real-World Management of Pemphigus}, journal = {Oral Diseases}, volume = {}, number = {}, pages = {-}, year = {2023} }
RIS	TY - JOUR AU - Mahmoudi H AU - Toosi R AU - Salehifarid A AU - Daneshpazhooh M TI - Pemphigus Disease and Area Index: Unmet Needs in the Real-World Management of Pemphigus JO - Oral Diseases VL - IS - SP - EP - PY - 2023 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract